ARQT
Arcutis Biotherapeutics, Inc.NASDAQHealthcare$23.63-1.95%ClosedMarket Cap: $2.93B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
16.01
P/S
7.80
EV/EBITDA
1100.40
DCF Value
$-154.91
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.2%
Operating Margin
-3.3%
Net Margin
-4.3%
ROE
-10.3%
ROA
-3.7%
ROIC
-4.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $129.5M | 91.0% | $18.4M | $17.4M | $0.13 | — |
| FY 2025 | $376.1M | 90.2% | $-12.2M | $-16.1M | $-0.13 | — |
| Q3 2025 | $99.2M | 91.2% | $8.5M | $7.4M | $0.06 | — |
| Q2 2025 | $81.5M | 90.8% | $-14.6M | $-15.9M | $-0.13 | — |
| Q1 2025 | $65.8M | 86.6% | $-24.5M | $-25.1M | $-0.20 | — |
| Q4 2024 | $71.4M | 90.3% | $-7.6M | $-10.8M | $-0.09 | — |
| FY 2024 | $196.5M | 90.3% | $-128.4M | $-140.0M | $-1.16 | — |
| Q3 2024 | $44.8M | 87.7% | $-39.1M | $-41.5M | $-0.33 | — |
| Q2 2024 | $30.9M | 88.8% | $-50.1M | $-52.3M | $-0.42 | — |
| Q1 2024 | $49.6M | 93.4% | $-31.6M | $-35.4M | $-0.32 | — |
| Q4 2023 | $13.5M | 83.4% | $-61.2M | $-66.3M | $-0.72 | — |
| FY 2023 | $59.6M | 91.6% | $-241.1M | $-262.1M | $-3.78 | — |